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Activation of the adenosine receptor pathway has been demonstrated to be effective
in improving tissue remodeling and blunting the inflammatory response. Active colitis is
characterized by an intense inflammatory reaction resulting in extensive tissue damage.
Symptomatic improvement requires both control of the inflammatory process and
repair and remodeling of damaged tissues. We investigated the ability of an A2A
receptor agonist, polydeoxyribonucleotide (PDRN), to restore tissue structural integrity
in two experimental colitis models using male Sprague-Dawley rats. In the first model,
colitis was induced with a single intra-colonic instillation of dinitrobenzenesulfonic acid
(DNBS), 25 mg diluted in 0.8 ml 50% ethanol. After 6 h, animals were randomized
to receive either PDRN (8 mg/kg/i.p.), or PDRN + the A2A antagonist [3,7-dimethyl-
1-propargylxanthine (DMPX); 10 mg/kg/i.p.], or vehicle (0.8 ml saline solution) daily. In
the second model, dextran sulfate sodium (DSS) was dissolved in drinking water at
a concentration of 8%. Control animals received standard drinking water. After 24 h
animals were randomized to receive PDRN or PDRN+DMPX as described above. Rats
were sacrificed 7 days after receiving DNBS or 5 days after DSS. In both experimental
models of colitis, PDRN ameliorated the clinical symptoms and weight loss associated
with disease as well as promoted the histological repair of damaged tissues. Moreover,
PDRN reduced expression of inflammatory cytokines, myeloperoxidase activity, and
malondialdehyde. All these effects were abolished by the concomitant administration
of the A2A antagonist DMPX. Our study suggests that PDRN may represent a promising
treatment for improving tissue repair during inflammatory bowel diseases.
Keywords: colitis, A2A agonist, PDRN, inflammation, apoptosis
INTRODUCTION
Inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis are chronic
diseases of the gastrointestinal tract characterized by inflammation of the enteric wall, abdominal
pain, diarrhea, bleeding, and malabsorption. The etiology of these diseases remain unknown,
although increasing evidence suggests that IBDs arise from altered immunological, genetic, and
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FIGURE 1 | Clinical evaluations. Food intake in DNBS-treated animals (A), weight loss in DNBS-treated animals (B), food intake in DSS-treated animals (C), and
weight loss in DSS-treated animals (D) was recorded. Values were obtained from seven animals per group and are expressed as means and SEM. ∗p < 0.01,
∗∗p < 0.001, ∗∗∗p < 0.0001 vs control group; #p < 0.01, ###p < 0.0001 vs DNBS/DSS+drug vehicle group; § p < 0.01, §§ p < 0.001, §§§ p < 0.0001 vs
DNBS/DSS+PDRN group.
environmental factors (Podolsky, 2002). The mucosal and
submucosal alterations characteristically observed in IBDs are
deep, longitudinal ulcerations, accompanied by hemorrhage,
submucosal edema and neutrophil infiltration. When IBDs
become chronic the colon becomes a rigid foreshortened tube
that lacks its usual haustral markings. These alterations are
due, at least in part, to the presence of pro-inflammatory
cells, free radicals, cytokines, eicosanoids, and chemotactic
factors (Pavlick et al., 2002; Rahimian et al., 2010). During
inflammation, the activation of nuclear factor-κB (NF-κB)
causes adaptive modifications in the damaged cells, promoting
the further production of pro-inflammatory mediators that
enlarge the extent of the damaged tissue (Shaulian and Karin,
2012). Specifically, activation of NF-κB increases tumor necrosis
factor-alpha (TNF-α) expression, which can induce either
apoptosis or necrosis depending on the targeted cell type,
environmental conditions, and magnitude of the cellular insult.
In addition, the death receptors tumor necrosis factor receptor
superfamily member 6 (FAS), tumor necrosis factor receptor
2 (TNFR2), TNF-related apoptosis-inducing ligand receptor 1
(TRAILR1), and TNF-related apoptosis-inducing ligand receptor
2 (TRAILR2), which are characteristically associated with
apoptosis, might also induce necrosis after caspase blockage or
starvation (Nunes et al., 2014).
Conventional therapies for IBD include anti-inflammatory
drugs, such as aminosalicylates, corticosteroids, thiopurines,
methotrexate, and anti-tumor necrosis factor agents (Burger and
Travis, 2011). The long-term use of these drugs can induce
severe side effects with a negative impact on patients’ quality of
life (Baumgart and Sandborn, 2007). For this reason, there is a
need for new, effective therapies with fewer side effects. Previous
studies have indicated that adenosine receptor stimulation
may down-regulate inflammation (Odashima et al., 2005). The
adenosine receptors (A1, A2A, A2B, and A3) are expressed on
immune/inflammatory cells, such as lymphocytes, neutrophils,
monocytes, and macrophages (Fortin et al., 2006; Desrosiers et al.,
2007). Moreover, it has been shown that stimulation of A2A
reduces pro-inflammatory cytokines in different disease models,
including asthma, arthritis, and sepsis (Haskó et al., 2008).
Our previous work (Bitto et al., 2011, 2013), has characterized
the anti-inflammatory and tissue repair activity of a specific
A2A receptor agonist, polydeoxyribonucleotide (PDRN) which is
extracted from trout (grown in aquaculture for feeding purposes)
with a registered method (Registration Dossier, Italian Ministry
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FIGURE 2 | Macroscopic evaluations. Colons (A) from control (1), DNBS+drug vehicle (2), DNBS+PDRN (3), DNBS+PDRN+DMPX (4) are depicted.
Macroscopic damage scores from the DNBS model and the DSS model are summarized in (B) and (C), respectively, while colon length is shown in (D) and (E) for
these models. Values were obtained from seven animals per group, and are expressed as the means and SEM. ∗∗∗p < 0.0001 vs control group; ##p < 0.001,
###p < 0.0001 vs DNBS/DSS+drug vehicle group; § p < 0.01, §§§ p < 0.0001 vs DNBS/DSS+PDRN group.
of Health; Rome, Italy). The purified PDRN contains a mixture
of polynucleotides, without contaminating pharmacologically
active proteins and peptides (data on file). The drug is already
on the market, therefore the eventually positive effects of this
agent may be promptly translated into clinics. PDRN has been
shown to improve tissue repair in animal models (Galeano et al.,
2008; Bitto et al., 2011) and has demonstrated efficacy in a
recent clinical trial (Squadrito et al., 2014). The purpose of this
study was to investigate the effects of PDRN in improving tissue
remodeling and reducing the inflammatory response during
experimental inflammatory colitis induced with either 2,4-
dinitrobenzenesulfonic acid (DNBS) or dextran sulfate sodium
(DSS) which are the most commonly used models for human
colitis.
MATERIALS AND METHODS
Animals and Drugs
All animal procedures were in accordance with the Principles
of Laboratory Animal Care (NIH publication no. 85-23, revised
1985), authorized by our Local Institution (protocol #03/2013),
and were in accordance with the ARRIVE Guidelines (McGrath
et al., 2010). A total of 56 male Sprague-Dawley rats (14 weeks
old, 250–300 g) were purchased from Charles River Laboratories
(Calco, Milan, Italy). Animals were maintained in plastic cages
under standard environmental conditions and feed ad libitum
in the Animal Facility of the Department of Clinical and
Experimental Medicine of the University of Messina, Messina,
Italy. Animals were allowed to acclimatize for 1 week before the
beginning of the experiments.
PDRN was a kind gift of Mastelli S.R.L. (Sanremo, Italy) and
was prepared fresh daily in a 0.9% NaCl solution. The dose
and route of administration were chosen according to previously
published reports (Galeano et al., 2008; Altavilla et al., 2011;
Bitto et al., 2011; Polito et al., 2012). DNBS was purchased from
Sigma-Aldrich (Milan, Italy) and dissolved in 50% ethanol. DSS
(MW = 36,000–50,000), was purchased from MP Biomedicals
(Solon, OH, USA) and prepared daily in fresh drinking water at
8%. 3,7-Dimethyl-1-propargylxanthine (DMPX), an antagonist
of A2A receptor, was purchased from Sigma-Aldrich and was
prepared fresh daily in dimethyl sulfoxide (DMSO) and then
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FIGURE 3 | Histological evaluations from DNBS-treated animals. Representative photomicrographs of H&E stained tissues (original magnification 10×) derived
from control (A), DNBS+drug vehicle (B), DNBS+PDRN (C), or DNBS+PDRN+DMPX (D) animals are shown. The graph represents the microscopic damage score
(E), where values are expressed as the means and SEM of seven animals. ∗∗∗p < 0.0001 vs control group; ###p < 0.0001 vs DNBS+drug vehicle group;
§§§p < 0.0001 vs DNBS+PDRN group. Scale bar 50 µm.
1:10 in saline. The dose and route of administration were
chosen according to previously published reports (Munzar et al.,
2002; Arolfo et al., 2004; Yao et al., 2006; Thorsell et al., 2007;
Balasubramanyan and Sharma, 2008)
DNBS Model
Colitis was induced in 21 fasted rats under light anesthesia by
a single intra-colonic instillation of DNBS (25 mg in 0.8 ml
50% ethanol) through a catheter that was inserted into the colon
(for 8 cm) via the anus up to the splenic flexure. Animals were
then kept for 15 min in Trendelenburg position to avoid reflux
and after 6 h were randomized to receive the vehicle (1 ml/kg;
n = 7), PDRN (8 mg/kg, n = 7), or PDRN+DMPX; (10 mg/kg;
n = 7) intraperitoneally. The treatment was administered daily
until the day of sacrifice. Control animals (n = 7) received
a single intra-colonic instillation of 0.8 ml saline solution.
At day 7, rats were sacrificed, the abdomen was opened by
a midline incision and the descending colon was removed,
opened along the anti-mesenteric border, rinsed and cut into
two equal pieces, one stored for histological assessments, the
other for measurement of biochemical markers. Blood was
collected by heart puncture, centrifuged, and kept frozen until
analysis.
DSS Model
Colitis was induced in 21 rats by oral administration of
8% DSS dissolved in drinking water from day 0 to day
5, as reported by Onishi et al. (2015). After 24 h, the
animals were randomized to receive either PDRN (n = 7),
or PDRN+DMPX (n = 7), or vehicle (n = 7) as above for
the duration of the study. Control animals (n = 7) received
standard drinking water. At day 5, animals were sacrificed,
blood and colon samples were collected and stored as described
above.
Clinical Assessment of Colitis
In both models the body weight, food intake, stool consistency,
rectal bleeding, or the presence of blood in the stool were
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FIGURE 4 | Histological evaluations from DSS-treated animals. Representative H&E images (original magnification 10×) of tissues derived from control (A),
DSS+drug vehicle (B), DSS+PDRN (C), or DSS+PDRN+DMPX (D) treated animals are shown here. The graph in (E) represents the microscopic damage score
values expressed as means and SEM derived from seven animals for each condition. ∗∗∗p < 0.0001 vs control group; ###p < 0.0001 vs DSS+drug vehicle group;
§§§ p < 0.0001 vs DSS+PDRN group. Scale bar 50 µm.
monitored daily for the duration of the study. Body weight
and food intake were recorded every day between 9:00 and
10:00 a.m. from the day of colitis induction to the end
of the experiment. Body weight results were expressed as
raw data and compared with food intake, by using the
following formula: food intake divided by body weight in
grams and multiplied by 100. In the DSS model water
consumption, from a graduated bottle was recorded every day
between 9:00 and 10:00 a.m. from day 0 to the end of the
experiment.
Macroscopic Damage Score
Colon length was measured and damage was scored by two
independent observers, as previously described (Wallace et al.,
1992), according to the following criteria: 0 (no damage), 1
(localized hyperemia without ulcers), 2 (linear ulcers with no
significant inflammation), 3 (linear ulcers with inflammation
at one site), 4 (two or more major sites of inflammation and
ulceration extending 1 cm along the length of the colon), and 5–8
(one point is added for each centimeter of ulceration beyond an
initial 2 cm).
Microscopic Damage Score
For light microscopy, colon tissues were fixed in 10% buffered
formalin for 24 h, then specimens were embedded in paraffin,
sectioned at 5 µm thickness, stained with hematoxylin
and eosin (H&E), and observed with a Leica microscope
(Leica Microsystems, Milan, Italy). Assessment of tissue
changes was carried out by two observers blinded to the
experimental protocol. The following morphological criteria
were considered: score 0 (no damage), score 1 (mild: focal
epithelial edema and necrosis), score 2 (moderate: diffuse
swelling and necrosis of the goblet cells), score 3 (severe:
necrosis and neutrophil infiltrate in the submucosa), score
4 (very severe: widespread necrosis with massive neutrophil
infiltrate and hemorrhage) as previously reported (Rahimian
et al., 2010).
Immunohistochemical Evaluation of Bax
and Bcl-2
Paraffin-embedded tissues were sectioned (5 µm), rehydrated,
and antigen retrieval was performed by using 0.05 M sodium
citrate buffer (pH 6.0) in a microwave for 5 min. Tissues
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FIGURE 5 | Bax immunostaining from DNBS-treated animals. Representative Bax immunostaining (original magnification 10×) of colons derived from control
(A), DNBS+drug vehicle (B), DNBS+PDRN (C), or DNBS+PDRN+DMPX (D) treated animals are depicted. The arrows in (A) and (C) point to areas of slight
positivity. The pictures in (B,D) demonstrate a diffuse staining for the apoptotic factor. Scale bar 50 µm.
were treated with 1% hydrogen peroxide to block endogenous
peroxidase activity, and with normal horse serum (Vector
Laboratories, Burlingame, CA, USA) to prevent non-specific
staining. Primary antibodies against either Bax (Abcam,
Cambridge, UK) or Bcl-2 (Cell Signaling Technologies Danvers,
MA, USA) were used and the slides were kept overnight at
4◦C in a humid box. The slides were then washed in phosphate
buffer sodium (PBS), the appropriate secondary antibody was
added, and the ABC system (Vectastain Elite ABC kit, Vector
Laboratories) was used to detect antibody localization. The
location of the reaction was visualized with diaminobenzidine
tetra-hydrochloride (Sigma-Aldrich, Milan, Italy). Slides were
counterstained with hematoxylin, dehydrated, and mounted with
coverslips. As a part of the histologic evaluation, all slides were
de-identified with regards to treatment group and evaluated by a
pathologist at 5× to 40× magnification with a Leica microscope
(Leica Microsystems, Milan, Italy).
Measurement of Myeloperoxidase
Activity
Myeloperoxidase (MPO), a marker of polymorphonuclear
leukocyte accumulation, was determined as previously described
(Mullane et al., 1985). Equal amounts of colon tissue were
homogenized mechanically with the MICCRA D-1 homogenizer
(Miccra Gmbh, Müllheim, Germany), in a solution containing
0.5% hexadecyltrimethylammonium bromide dissolved in
10 mM potassium phosphate buffer (pH 7.0). Lysates were then
centrifuged for 30 min at 15,000 rpm at 4◦C. An aliquot of the
supernatant was allowed to react with a solution of 1.6 mM
tetra-methyl-benzidine and 0.1 mM H2O2. The absorbance was
measured with a spectrophotometer at 650 nm. MPO activity was
defined as the quantity of enzyme degrading 1 µmol hydrogen
peroxide/min at 37◦C and was expressed in units per gram of
tissue.
Malondialdehyde Measurement
The levels of malondialdehyde (MDA) in the colon were
determined as an indicator of lipid peroxidation (Ohkawa
et al., 1979). Equal amounts of colon tissue were homogenized
mechanically with the MICCRA D-1 homogenizer (Miccra
Gmbh, Müllheim, Germany), in 1.15% KCl solution, a 0.1 ml
aliquot of the homogenate was added to a reaction mixture
containing 0.2 ml of 8.1% sodium dodecyl sulfate (SDS),
1.5 ml of 20% acetic acid, 1.5 ml of 0.8% thiobarbituric acid
and 700 ml distilled water. Samples were boiled for 1 h at
95◦C and centrifuged at 3000×g for 10 min. The absorbance
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FIGURE 6 | Bcl-2 immunostaining from DNBS-treated animals. Representative Bcl-2 immunostaining (original magnification 10×) of tissues derived from
control (A), DNBS+drug vehicle (B), DNBS+PDRN (C), or DNBS+PDRN+DMPX (D) treated animals are depicted. The images in (A,C) demonstrate diffuse Bcl-2
staining, while the arrows in (B,D) point to the residual Bcl-2 staining in the mucosal layer. Scale bar 50 µm.
of the supernatant was measured by spectrophotometer at
650 nm.
Evaluation of IL-1β and TNF-α
Serum samples were assayed in duplicate using commercially
available enzyme linked immunosorbent assay (ELISA) kits for
Interleukin 1 beta (IL-1β) and TNF-α (Abcam, Cambridge, UK).
The absorbance was read at 405 nm and the results were obtained
interpolating the measurements with the respective standard
curves. For each sample, the mean of the duplicates was used and
expressed in pg/ml.
Statistical Analysis
All quantitative data are expressed as mean ± SEM for each
group and compared by one-way or two-way ANOVA for
non-parametric variables with Tukey’s post-test for intergroup
comparisons. Statistical significance was set at p < 0.05. Graphs
were drawn using GraphPad Prism software version 5.0 for
Windows (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
Effects of PDRN on Clinical Signs
Colitis was successfully induced in rats as early as 6 h
after DNBS treatment as demonstrated by the appearance of
diarrhea followed by significant loss in body weight from
day 3. PDRN-treated animals demonstrated an initial slight
weight reduction (not significant) followed by a recovery by
the end of the experiment (p < 0.0001 vs animals treated with
DNBS+drug vehicle) with the appearance of solid feces after 3
days (Figures 1A,B). The concomitant administration of DMPX
prevented weight and appetite loss in the DNBS+PDRN+DMPX
group. Furthermore, at the end of the study, this group still
had diarrhea, suggesting that DMPX completely blocked the
effectiveness of PDRN in these animals (Figures 1A,B).
DSS-administered animals showed diarrhea and rectal
bleeding after 24 h, while weight reduction was observed
starting from day 3 (p < 0.0001 vs control group at the end of
experiment). Treatment with PDRN resulted in reduced bleeding
and improved food intake and body weight (p < 0.0001 vs
DSS+drug vehicle at the end of the experiment; Figures 1C,D).
DMPX abolished the positive effect of PDRN on food intake
and body weight in DSS administered animals. Rectal bleeding
was still present in these animals at the end of the study,
indicating that DMPX fully antagonized the effects of PDRN
(Figures 1C,D).
Effects of PDRN on Macroscopic
Damage
At the end of the experiment, the colon of animals in the
DNBS+drug vehicle group appeared ulcerated, edematous,
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FIGURE 7 | Bax immunostaining from DSS-treated animals. Representative Bax immunostaining (original magnification 10×) of colons derived from control (A),
DSS+drug vehicle (B), DSS+PDRN (C), or DSS+PDRN+DMPX (D) treated animals are shown. The arrows in (A,C) point to regions of slight positivity. The pictures
in (B,D) demonstrate a diffuse staining for the apoptotic factor. Scale bar 50 µm.
and hyperemic compared to control group (p < 0.0001;
Figures 2A,B). In the group treated with PDRN a significant
reduction in the extent and severity of colon injury was observed
(p < 0.0001 vs DNBS+drug vehicle group; Figures 2A,B). As
shown in Figure 2D, DNBS also caused a significant shortening
of the colon, as compared to control animals (p < 0.0001).
Treatment with PDRN significantly improved this condition. The
positive effects of PDRN administration on macroscopic damage
were blunted by DMPX (Figures 2A–D).
In the DSS+drug vehicle group, as well as in the
DSS+PDRN+DMPX group, the presence of non-formed
feces and blood was observed at the end of the study. However,
the animals receiving PDRN demonstrated normal colon
appearance in contrast to the animals that did not receive PDRN
(Figure 2C). As shown in Figure 2E, DSS caused a significant
reduction in colonic length as compared to control animals
(p < 0.0001). Treatment with PDRN significantly improved this
condition. No difference was observed in water consumption
among groups during the study period.
PDRN Reduces Histological Damage
A normal appearance of the colonic mucosa with intact
epithelium was observed in the control group (Figures 3A,E).
DNBS administration resulted in epithelial necrosis, massive
infiltration of neutrophils and macrophages into the mucosal
and submucosal layers, thickening of the colon wall, loss of
goblet cells and edema (Figures 3B,E). The administration of
PDRN resulted in: (i) a significant reduction in the extent and
severity of epithelial and mucosal alterations; (ii) regeneration of
the epithelium with preservation of crypts and goblet cells; and
(iii) reduced infiltration of inflammatory cells (Figures 3C,E).
Blockade of the adenosine receptor with DMPX counteracted the
beneficial effects of PDRN (Figures 3D,E).
In the DSS model, the histological analysis showed a
flattening of the mucosa with a reduced presence of mucosal
glands, a massive inflammatory infiltrate and edema in the
submucosal layer (Figures 4B,E) as compared to control animals
(Figures 4A,E). Treatment with PDRN significantly reduced
the extent and severity of the histological alteration associated
with DSS administration and stimulated regeneration of the
epithelium, crypts, and goblet cells (Figures 4C,E). DMPX
administration abrogated the protective effects of PDRN on
histological features (Figures 4D,E).
Effects of PDRN on Apoptosis Markers
Tissues taken from control rats of both experimental models
demonstrated, as expected, very little staining for Bax
(Figure 5A). Sections obtained from the DNBS+drug vehicle
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FIGURE 8 | Bcl-2 immunostaining from DSS-treated animals. Representative images of Bcl-2 immunostaining (original magnification 10×) of colons derived
from control (A), DSS+drug vehicle (B), DSS+PDRN (C), or DSS+PDRN+DMPX (D) treated animals are shown. The image in (A,C) demonstrate diffuse staining for
Bcl-2, while the arrows in (B,D) point to residual Bcl-2 staining in the mucosal layer. Scale bar 50 µm.
group exhibited a diffuse positive staining for Bax (Figure 5B),
demonstrating the activation of apoptosis in the epithelial
and submucosal layers. PDRN administration markedly
reduced the degree of Bax positive staining, almost restoring
a normal appearance of the colon (Figure 5C), while DMPX
co-administration abrogated the protective effect of PDRN
(Figure 5D). The Bcl-2 staining in the control group from both
experiments was highly positive (Figures 6A and 8A). DNBS
administration almost abrogated the presence of Bcl-2 due to
the massive necrosis of the tissue (Figure 6B). PDRN treatment
restored the presence of Bcl-2 (Figure 6C) in the newly formed
mucosal layer, however, when co-administered with DMPX the
beneficial effects were no longer observed (Figure 6D).
In the DSS model, the immunostaining for Bax revealed
wide expression of the pro-apoptotic molecule in DSS animals
compared to controls (Figures 7A,B) that was reduced to basal
levels by PDRN treatment (Figure 7C). A strong reduction in
Bcl-2 staining was observed in the DSS+drug vehicle group
(Figure 8B). The administration of PDRN was able to restore
Bcl-2 positivity in the regenerated tissue (Figure 8C). The
co-administration of DMPX blunted the effects of PDRN on Bax
and Bcl-2 expression (Figures 7D and 8D).
Effects of PDRN on Lipid Peroxidation
and Neutrophil Infiltration
MDA levels and MPO activity were increased in the groups
of animals that received DNBS+drug vehicle and DSS+drug
vehicle (Figures 9A–D). The administration of PDRN markedly
reduced both lipid peroxidation and the accumulation of
polymorphonuclear granulocytes, in both experimental models
(Figures 9A–D). DMPX, abolished the protective effects of
PDRN on both MDA level and MPO activity (Figures 9A–D).
Effects of PDRN on IL-1 β and TNF-α
levels
Circulating levels of the proinflammatory cytokines IL-1β and
TNF-α were measured 7 days after DNBS administration. As
shown in Figures 10A,B, a significant increase in both IL-1β
and TNF-α was found in serum from DNBS+drug vehicle group
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FIGURE 9 | Evaluation of inflammatory markers. The effects of PDRN on malondialdehyde levels and myeloperoxidase activity in DNBS-treated animals are
shown in (A) and (B), respectively, while the consequences of PDRN treatment on malondialdehyde levels and myeloperoxidase activity in the DSS model are
summarized in (C) and (D), respectively. All values are expressed as means and SEM based on observations made on seven animals per group. ∗∗∗p < 0.0001 vs
control group; ###p < 0.0001 vs DNBS/DSS+drug vehicle group; §§§ p < 0.0001 vs DNBS/DSS+PDRN group.
compared to control animals (p < 0.0001). A2A stimulation
reduced the serum levels of IL-1β and TNF-α significantly
(p < 0.0001 vs DNBS+drug vehicle group). In the DSS model,
IL-1β and TNF-α were similarly upregulated (Figures 10C,D),
and PDRN reduced their expression. Again, PDRN failed to elicit
an inhibitory effect on cytokine levels in the presence of DMPX
(Figures 10A–D).
DISCUSSION
Despite the unknown etiology of IBDs, oxidative stress appears to
have an important role in the development of epithelial damage,
altered immune response, and increased cytokine production
(Rachmilewitz et al., 1993; Grisham, 1994; Strober and Fuss,
2011). The intracellular pathways triggered by adenosine receptor
stimulation have a well-recognized role in modulating the
inflammatory cascade in the gastro-intestinal tract and elsewhere
(Antonioli et al., 2010). All four adenosine receptors, A1, A2A,
A2B, and A3, are expressed in colonic epithelial cells. In addition,
A1 receptors were found to be expressed in circular muscle,
while A2A receptors were detected in both circular muscle and
myenteric plexus (Barrett et al., 1989; Fornai et al., 2009; Lam
et al., 2009). It has been previously reported that the activation
of A2A modulates the inflammatory response and stimulates
epithelial repair in experimental colitis (Antonioli et al., 2011,
2014). Moreover, when colitis was induced in A2A knockout
mice via Clostridium difficile infection, knockout animals had
a worse outcome compared to wild type littermates (Li et al.,
2012), further supporting a role for A2A receptor in colitis.
In addition, A2B stimulation has recently been shown to have
a protective role in colitis (Aherne et al., 2015) and protects
the colonic epithelial barrier during acute colitis via enhancing
mucosal barrier responses.
Previous findings in several mouse models of inflammatory
and immune disease (Haskó et al., 2008) and in other animal
models of IBD (Odashima et al., 2005; Cavalcante et al., 2006)
have demonstrated the efficacy of A2A receptor stimulation.
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FIGURE 10 | Evaluation of inflammatory cytokines. Serum of DNBS- or DSS-challenged animals was extracted, and Interleukin 1β (IL-1β) (A,C) and tumor
necrosis factor-alpha (TNF-α) (B,D) levels were determined by enzyme linked immunosorbent assay (ELISA). Values shown here are expressed as the means and
SEM of seven animals per group. ∗∗∗p < 0.0001 vs control group; #p < 0.01, ###p < 0.0001 vs DNBS/DSS+drug vehicle group; § p < 0.01, §§§ p < 0.0001 vs
DNBS/DSS+PDRN group.
Therefore, it is not surprising that PDRN restores the enteric
mucosa in these colitis models. Although it seems unlikely, due
to different route of administration and mechanism of action, it
should be acknowledged that PDRN could mitigate symptoms
by interfering with the damaging agents (DNBS and DSS). On
the other hand, it has been suggested that adenosine generated
by the catabolizing enzyme CD73 during bacterial infection can
contribute to immunosuppression leading to increased pathogen
load (Alam et al., 2015). Our present data do not support an
increase in tissue damage due to adenosine receptor stimulation.
Rather, we provide further evidence that this strategy could
efficaciously halt inflammation in IBD.
Of importance, the studies described utilized a compound
with an excellent safety profile that is already on the market in
some countries, including Italy. Some of the approved drugs used
in clinical practice for IBDs, such as mesalazine, cyclosporine,
and non-steroidal anti-inflammatory drugs (NSAIDs), have a
proven efficacy in symptoms reduction, similarly PDRN was
effective in reducing the symptoms and clinical signs, under the
experimental conditions described. However, as demonstrated by
a recent clinical trial, PDRN is better tolerated and elicits less side
effects than common NSAIDs (Squadrito et al., 2014). Despite
the fact that no epidemiological data is available regarding the
efficacy of PDRN in IBD, it has previously been shown to reduce
inflammation in other models (Bitto et al., 2011). To date, none of
the previously used experimental drugs that bind to the adenosine
receptors have been clinically evaluated. However, since PDRN
is currently on the market (for the treatment of poor wound
healing), PDRN represents an entity that could be tested in
IBD trials. The data presented here strongly suggest that the
compound is worthy of study in a human IBD population. In this
regard, preliminary pharmacokinetics data obtained in mice posit
that PDRN has a half life of approximately 12–17 h (unpublished
observations), suggesting it might be suitable for once a day
dosing.
In agreement with previous observations, our results
demonstrated the beneficial effects of PDRN in two experimental
model of colitis. The early onset of the protective effect of
PDRN was able to blunt the hemorrhagic diarrhea, improve
the loss of weight, and to restore the anatomic integrity of
damaged epithelial and mucosal layers. PDRN markedly reduced
the inflammatory response and granulocytic infiltration into
the mucosal and submucosal layers and, as a consequence,
reduced the presence of the circulating pro-inflammatory
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cytokines TNF-α and IL-1β and reduced MPO activity and lipid
peroxidation extent evaluated by MDA in colon samples. PDRN
treatment also affected Bax and Bcl-2 expression in experimental
colitis reducing apoptotic and necrotic cells in all tissue layers.
In previous experiments PDRN was shown to improve tissue
repair (Galeano et al., 2008; Bitto et al., 2011) by reducing
inflammatory cytokines and increasing tissue growth factor-beta
(TGF-β) and transglutaminase II which are key mediators of
tissue remodeling. In a recent clinical trial, Squadrito et al. (2014)
confirmed the relevance of these findings by demonstrating that
patients with diabetic foot ulcers treated with PDRN had a
shorter healing time and lower incidence of wound infections.
The same trial also suggested that PDRN efficacy is not related to
gender, as the multivariate analysis demonstrated the same rate
of healing in both sexes (Squadrito et al., 2014). However, in the
present study we have tested PDRN efficacy only in male rats
and this can limit the interpretation of these findings to IBD in
general.
The mechanism(s) by which PDRN ameliorates experimental
colitis are, as yet, undefined though evidence suggests that the
effect may be mediated by modulation of inflammatory cell
activity. Macrophages are known to have an important role in
the induction of tissue injury during colitis and the activation
of A2A receptor has a potent macrophage-deactivating effect
(Haskò et al., 2000; Kreckler et al., 2006). Activation of the
A2A receptor also modulates neutrophil function, regulates the
production of reactive oxygen species by these cells (Cronstein
et al., 1983, 1985), inhibits the localization of neutrophils to
the endothelium by decreasing the expression of the adhesion
molecules expressed on neutrophils (Sullivan et al., 2004),
and reduces apoptosis of colonic mucosal cells (Mayne et al.,
2001).
The A2A antagonist, DMPX, was used to confirm the target
of PDRN activity in our experiments and, indeed, abrogated all
the therapeutic effects obtained with PDRN. However, recent
evidence suggests that DMPX also blocks A2B (Wang et al.,
2015). Therefore, it is possible that PDRN could effectively
work through other adenosine receptors, including A2B. We did
not investigate the effects of DMPX alone, which will probably
worsen the colitis features, because we wanted to keep to the
minimum the number of animals used in this painful procedure,
according to the 3Rs principles of animal studies.
CONCLUSION
In this study we demonstrated that PDRN, a safe and
readily available A2A receptor agonist produced a significant
improvement in all the pathological outcomes associated with
inflammatory colitis.
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